Tofajak 5mg, also referred to as Tofacitinib 5mg, is a Janus kinases (JAKs) inhibitor that has received approval for treating various medical conditions, which include:
Moderately to severely active rheumatoid arthritis in adult patients who have not responded positively to methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs). Jaknat 5mg can be administered alone or combined with methotrexate or other non-biologic DMARDs. However, it is not advisable to use it concurrently with biologic DMARDs or potent immunosuppressants like azathioprine and cyclosporine.
Active psoriatic arthritis in adult patients who have not shown positive responses to methotrexate or other DMARDs. Similar to its use in rheumatoid arthritis, Jaknat 5mg can be used alone or combined with other non-biologic DMARDs but not with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine.
Moderately to severely active ulcerative colitis (UC) in adult patients who have not responded positively to TNF blockers or are intolerant to them. However, using Jaknat 5mg concurrently with biologic therapies for UC or potent immunosuppressants such as azathioprine and cyclosporine is not advisable.
Active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients aged two years and above. The oral solution of Tofacitinib is recommended for this use. Nevertheless, it should not be used together with biologic DMARDs or potent immunosuppressants like azathioprine and cyclosporine.
In the treatment of Rheumatoid Arthritis, the recommended dosing for Tofacitinib is 5 mg taken twice daily or 11 mg taken once daily. However, for patients with moderate to severe renal impairment or moderate hepatic impairment, the recommended dosing is 5 mg once daily. It is important to note that Tofacitinib 11 mg should not be used in patients with severe hepatic impairment. In addition, some studies suggest that turmeric supplements may be beneficial for joint pain relief in patients with arthritis.
For Psoriatic Arthritis, the recommended dosing for Tofacitinib is 5 mg taken twice daily in combination with nonbiologic DMARDs or 11 mg taken once daily in combination with nonbiologic DMARDs. Similar to Rheumatoid Arthritis, the recommended dosing for patients with moderate to severe renal impairment or moderate hepatic impairment is 5 mg once daily. Tofacitinib 11 mg should not be used in patients with severe hepatic impairment.
For the treatment of Ulcerative Colitis, the recommended dosing for Tofacitinib is 10 mg taken twice daily or 22 mg taken once daily for 8 weeks for induction. After the induction period, patients should be evaluated and transitioned to maintenance therapy based on their therapeutic response. If necessary, Tofacitinib can be continued at 10 mg twice daily or 22 mg once daily for a maximum of 16 weeks. If a therapeutic response is not achieved after 16 weeks, Tofacitinib should be discontinued. For maintenance therapy, the recommended dosing is 5 mg taken twice daily or 11 mg taken once daily. If a patient experiences a loss of response during maintenance treatment, Tofacitinib 10 mg twice daily or 22 mg once daily may be considered, but only for the shortest duration possible and with careful consideration of the risks and benefits for the individual patient. The lowest effective dose needed to maintain a response should be used. Dosage adjustment is necessary for patients with moderate and severe renal impairment or moderate hepatic impairment.
Finally, for the treatment of Polyarticular Course Juvenile Idiopathic Arthritis, the recommended dosing for Tofacitinib Oral Solution is 5 mg taken twice daily or weight-based equivalent twice daily. Dosage adjustment is also necessary for patients with moderate and severe renal impairment or moderate hepatic impairment. Please consult the full prescribing information for additional details.
Tofacitinib Side Effects：
TOFACITINIB 5MG/11MG is a medication that affects the immune system, which can decrease your body's ability to fight infections, including serious ones like tuberculosis, bacterial, fungal, or viral infections that can spread throughout the body. Some infections may even result in death. Before starting and during treatment with TOFACITINIB 5MG/11MG, your healthcare provider must test you for tuberculosis and monitor you closely for any signs of infection.
It is not safe to take TOFACITINIB 5MG/11MG if you currently have any infection, unless your healthcare provider says it is safe to do so. Inform your healthcare provider of your medical history, especially if you have a history of infections, diabetes, chronic lung disease, HIV, weak immune system, or if you live in or have traveled to areas where fungal infections are common. Contact your healthcare provider immediately if you experience symptoms of infection such as fever, cough, or diarrhea.
Taking TOFACITINIB 5MG/11MG may increase your risk of certain types of cancer, including lymphoma and skin cancer. Inform your healthcare provider if you have ever had cancer. Moreover, some people who have taken TOFACITINIB with certain other medicines have experienced a problem with white blood cells growing out of control.
Taking TOFACITINIB 5MG/11MG may also increase the risk of tears in the stomach or intestines, especially if you also take nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, or methotrexate. Inform your healthcare provider if you have had diverticulitis or ulcers in your stomach or intestines. Contact your healthcare provider immediately if you experience fever and stomach-area pain that does not go away, or a change in bowel habits.
While taking TOFACITINIB 5MG/11MG, your healthcare provider should regularly check certain blood tests, including lymphocyte, neutrophil, and red blood cell counts, as well as liver tests. If any of these test results are abnormal, your healthcare provider may temporarily stop treatment. You may also need to have your blood cholesterol levels checked regularly as taking TOFACITINIB 5MG/11MG may affect your cholesterol levels, which are important for good heart health.
Tofacitinib cost in India：
The cost of purchasing Tofacitinib online from an Indian pharmacy is only 9% of the brand-name version.
|Don't take the drug without consulting a qualified doctor or physician
|Follow the doctor's advice
|Delivery & Returns